Genmab (NASDAQ:GMAB) has received diverse analyst ratings in the last three months, with 5 analysts offering views ranging from bullish to somewhat bearish. The average 12-month price target is $45.8, with a high of $50.00 and a low of $32.00, reflecting a 3.32% increase from the previous average of $44.33. Analyst Raghuram Selvaraju from HC Wainwright & Co. has adjusted his price target and maintained a 'Buy' rating, while Matthew Harrison from Morgan Stanley has lowered his rating to 'Underweight' with a price target of $32.00. Genmab, a biotech company specializing in antibody therapeutics, has shown a revenue growth rate of 16.08% and a high net margin of 44.88%, but its revenue growth lags behind industry peers. The company's financial health is strong, with an ROE of 7.11% and an ROA of 6.33%, and a low debt-to-equity ratio of 0.03.